QUASAR Induction Study 1 Cumulative Response to Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis

被引：0

作者：

Peyrin-Biroulet, L. ^{[1
]}

Rubin, D. ^{[2
]}

Lichtenstein, G. ^{[3
]}

Shipitofsky, N. ^{[4
]}

Huang, K. H. ^{[4
]}

Germinaro, M. ^{[4
]}

Wilson, R. ^{[5
]}

Zhang, H. ^{[5
]}

DuVall, G. A. ^{[6
]}

Cao, Q. ^{[7
]}

Allegretti, J. ^{[8
]}

Feagan, B. ^{[9
]}

Hisamatsu, T. ^{[10
]}

Panes, J. ^{[11
]}

Dignass, A. ^{[12
]}

Bressler, B. ^{[13
]}

Sands, B. ^{[14
]}

机构：

[1] Nancy Univ Hosp, Gastroenterol, Nancy, France

[2] Univ Chicago Med, Ctr Inflammatory Bowel Dis, Chicago, IL USA

[3] Univ Pennsylvania, Dept Med, Div Gastroenterol, Raymond & Ruth Perelman Sch, Philadelphia, PA USA

[4] Janssen Res Dev LLC, Immunol, Spring House, PA USA

[5] anssen Res Dev LLC, Biostat, Spring House, PA USA

[6] Tyler Res Inst LLC, Gastroenterol, Tyler, TX USA

[7] Zhejiang Univ, Sch Med, Hangzhou, Peoples R China

[8] Brigham & Womens Hosp, Crohns & Colitis Ctr, Gastroenterol Hepatol & Endoscopy, Boston, MA USA

[9] Alimentiv Inc, Gastroenterol, London, ON, Canada

[10] Kyorin Univ, Gastroenterol & Hepatol, Tokyo, Japan

[11] CIBERehd, Gastroenterol, Hosp Clin Barcelona, IDIBAPS, Barcelona, Spain

[12] Agaples Markus Hosp, Dept Med, Frankfurt, Germany

[13] Univ British Columbia, Div Gastroenterol, Vancouver, BC, Canada

[14] Icahn Sch Med Mt Sinai, Dr Henry Janowitz Div Gastroenterol, New York, NY USA

来源：

JOURNAL OF CROHNS & COLITIS | 2023年 / 17卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

P493

引用

页码：624 / 625

页数：3

共 50 条

[41] The efficacy and safety of adalimumab for patients with moderately to severely active ulcerative colitis and predictors of response in Korea
Shin, S. Shin
Park, S. J.
Kim, Y.
Im, J. P.
Kim, H. J.
Lee, K. M.
Kim, J. W.
Jung, S. A.
Lee, J.
Kang, S. B.
Shin, S. J.
Kim, E. S.
Kim, Y. S.
Kim, T. O.
Kim, H. S.
Park, D. I.
Kim, H. K.
Kim, E. S.
Kim, Y. H.
Kim, D. H.
Teng, D.
Kim, J. H.
Kim, W. Y.
Choi, C. H.
JOURNAL OF CROHNS & COLITIS, 2020, 14 : S432 - S432
[42] Vedolizumab for the Treatment of Moderately to Severely Active Ulcerative Colitis
Dulai, Parambir S.
Mosli, Mahmoud
Khanna, Reena
Levesque, Barrett G.
Sandborn, William J.
Feagan, Brian G.
PHARMACOTHERAPY, 2015, 35 (04): : 412 - 423
[43] Early Symptom Control With Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis in the LUCENT-1 Induction Trial
Danese, Silvio
Dignass, Axel
Matsuoka, Katsuyoshi
Ferrante, Marc
Long, Millie
Redondo, Isabel
Gibble, Theresa Hunter
Moses, Richard
Morris, Nathan
Li, Xingyuan
Milch, Catherine
Abreu, Maria T.
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S535 - S535
[44] Histologic and Combined Histologic and Endoscopic Outcomes After Guselkumab Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Week 44 Results From the Phase 3 QUASAR Maintenance Study
Panes, Julian
Dignass, Axel
Hisamatsu, Tadakazu
Yarandi, Shadi
Huang, Kuan-Hsiang G.
Germinaro, Matthew
Sridhar, Sunandini
Branigan, Patrick
Wilson, Rebbecca
Zhang, Hongyan
Magro, Fernando
Jairath, Vipul
Feagan, Brian G.
Lichtenstein, Gary R.
Rubin, David T.
Sands, Bruce E.
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S1041 - S1041
[45] Combination Therapy With Guselkumab and Golimumab in Patients With Moderately to Severely Active Ulcerative Colitis: Pharmacokinetics, Immunogenicity and Drug-Drug Interactions
Shao, Jie
Vetter, Marion
Vermeulen, An
Feagan, Brian G.
Sands, Bruce E.
Panes, Julian
Xu, Zhenhua
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 (06) : 1418 - 1427
[46] Trajectories of response in patients with moderately-to-severely active ulcerative colitis treated with mirikizumab: Results from the LUCENT-1 study
Schreiber, S. W.
Clemow, D. B.
Keohane, A.
Zhu, B.
Ritter, T.
Regueiro, M.
Hudesman, D.
Chen, Y. F.
Owen, C.
JOURNAL OF CROHNS & COLITIS, 2025, 19 : I1975 - I1976
[47] Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis
Yasuo Suzuki
Satoshi Motoya
Hiroyuki Hanai
Takayuki Matsumoto
Toshifumi Hibi
Anne M. Robinson
Nael M. Mostafa
Jingdong Chao
Vipin Arora
Anne Camez
Roopal B. Thakkar
Mamoru Watanabe
Journal of Gastroenterology, 2014, 49 : 283 - 294
[48] Integrated summary of safety of obefazimod for patients with moderately to severely active ulcerative colitis
Vermeire, S.
Peyrin-Biroulet, L.
Danese, S.
Dubinsky, M.
Dulai, P. S.
Tilg, H.
Siegmund, B.
Hisamatsu, T.
Shan, K.
Jacobstein, D.
Cataldi, F.
Rabbat, C.
Sands, B. E.
JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1554 - i1555
[49] Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis
Suzuki, Yasuo
Motoya, Satoshi
Hanai, Hiroyuki
Matsumoto, Takayuki
Hibi, Toshifumi
Robinson, Anne M.
Mostafa, Nael M.
Chao, Jingdong
Arora, Vipin
Camez, Anne
Thakkar, Roopal B.
Watanabe, Mamoru
JOURNAL OF GASTROENTEROLOGY, 2014, 49 (02) : 283 - 294
[50] Risankizumab Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Efficacy and Safety in the Randomized Phase 3 INSPIRE Study
Louis, Edouard
Panaccione, Remo
Parkes, Gareth
Peyrin-Biroulet, Laurent
Ferrante, Marc
Takeuchi, Ken
Siegmund, Britta
Levine, Phillip
Kalabic, Jasmina
Neimark, Ezequiel
Wallace, Kori
Chen, Su
Duan, W. Rachel
Armuzzi, Alessandro
Biedermann, Luc
Loftus, Edward V.
Melmed, Gil
Schreiber, Stefan
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S624 - S625

← 1 2 3 4 5 →